Understanding Lung Cancer Related Risk Factors and Their Impact
ConditionLung Cancer Screening
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-80
SponsorBiobizkaia Health Research Institute
About this trial
LUCIA aims to develop prediction models for the early diagnosis of lung cancer based on the identification of risk factors and deeper cellular knowledge, by recording real-world data; with risk assessment tools, non-invasive devices and omics analysis. These models will enable new clinical pathways and diagnostic workflow to be implemented to ensure early diagnosis and confirmation, including classification of lung cancer subtype.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Subjects aged between 40 and 80 years
Both genders, of which at least 37% must be women to ensure representativeness
Willingness and ability to comply with scheduled visits, laboratory tests, and other trial procedures
Written informed consent obtained prior to performing any protocol-related procedures.
Disqualifiers
Subjects under 40 years of age
Unable to be followed-up for at least 2-years or complete the study
Subjects that do not sign the informed consent
Current or prior history of lung cancer
Trial population
Adult subjects (40 years old or higher), smokers and non-smokers, both women and men who have the capacity to comply with the study follow-up and sign the informed consent, will be recruited from "Servicio Andaluz de Salud" (SAS), "Osakidetza Servicio Vasco de Salud" (OSA), "Centre Hospitalier Universitaire de Liège" (CHUL) and "Centre for Tuberculosis and Lung Diseases (CTLD) of Riga East University Hospital (REUH)".
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
6,160 Participants
are grouped into 1 trial groupGroup A: Study population
Trial outcomes
Primary outcomes
1
presence of pulmonary nodules
The main variable is the presence of pulmonary nodules identified by Low Dose Computerized Tomography (LDCT)
Time frame
2 years2
Lung Cancer diagnosis
The main variable is the presence of Lung Cancer diagnosis identified by Low Dose Computerized Tomography (LDCT).
Time frame
2 yearsSecondary outcomes
1
Age
years
Time frame
2 years2
Gender
Male/female
Time frame
2 years3
Ethnicity
description of the ethnia
Time frame
2 years4
Socioeconomic factors
deprivation index
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Biobizkaia Health Research Institute
Lead sponsor
Technion, Israel Institute of Technology
Collaborator
Centro Nacional de Análisis Genómico
Collaborator
Vicomtech
Collaborator
University of Latvia
Collaborator
Centre Hospitalier Universitaire de Liege
Collaborator
Andaluz Health Service
Collaborator
Nanose Medical Ltd.
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: